Emerald Mutual Fund Advisers Trust Sells 166,165 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Emerald Mutual Fund Advisers Trust cut its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 13.5% in the 4th quarter, HoldingsChannel reports. The firm owned 1,067,400 shares of the medical research company’s stock after selling 166,165 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in NeoGenomics were worth $17,591,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Franklin Resources Inc. increased its holdings in shares of NeoGenomics by 2.0% in the third quarter. Franklin Resources Inc. now owns 2,043,840 shares of the medical research company’s stock worth $28,225,000 after buying an additional 39,740 shares during the period. Versant Capital Management Inc raised its holdings in NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after buying an additional 1,142 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of NeoGenomics by 2.8% in the fourth quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company’s stock worth $1,301,000 after purchasing an additional 2,125 shares during the last quarter. Moody National Bank Trust Division increased its stake in shares of NeoGenomics by 20.2% during the fourth quarter. Moody National Bank Trust Division now owns 73,226 shares of the medical research company’s stock valued at $1,207,000 after buying an additional 12,314 shares during the period. Finally, Mitsubishi UFJ Asset Management UK Ltd. raised its holdings in NeoGenomics by 16.7% in the 4th quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 56,000 shares of the medical research company’s stock worth $923,000 after purchasing an additional 8,000 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Needham & Company LLC reduced their price target on NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Benchmark cut NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. The Goldman Sachs Group lowered their price target on NeoGenomics from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. Piper Sandler cut their target price on shares of NeoGenomics from $21.00 to $18.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Finally, Bank of America cut their price target on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, February 19th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.30.

NeoGenomics Stock Performance

NASDAQ NEO opened at $9.97 on Tuesday. The company has a market cap of $1.28 billion, a P/E ratio of -16.08 and a beta of 1.41. NeoGenomics, Inc. has a 1-year low of $8.05 and a 1-year high of $19.12. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The stock has a 50-day moving average of $9.74 and a two-hundred day moving average of $13.45.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The company had revenue of $172.00 million for the quarter, compared to analysts’ expectations of $173.40 million. As a group, analysts anticipate that NeoGenomics, Inc. will post -0.2 EPS for the current year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.